Chronic Myelogenous Leukemia News and Research

Latest Chronic Myelogenous Leukemia News and Research

Vaccine improves event-free survival for leukemia patients

Patients whose immune system responded to a peptide vaccine for leukemia enjoyed a median remission that was more than three times longer than non-responders, a team led by researchers at The University of Texas M. D. Anderson Cancer Center reports at the 49th Annual Meeting of the American Society of Hematology.

10 Dec 2007

New role for miRNA in leukemia discovered

Scientists here have found that mini-molecules called micro-RNA may play a critical role in the progression of chronic myeloid leukemia (CML) from its more treatable chronic phase to a life-threatening phase, called blast crisis.

10 Dec 2007

New understanding of chronic myeloid leukemia

Oregon Health & Science University Cancer Institute researchers have opened a new window into the roots of chronic myeloid leukemia (CML).

10 Dec 2007

More good Gleevec news

Gleevec, the targeted cancer pill that has saved more than 100,000 lives, now is saving more children with a dire leukemia, as well as preventing disease progression with long term use in adults with chronic myeloid leukemia.

10 Dec 2007

Nilotinib and Dasatinib show promise as therapy for chronic myelogenous leukemia

Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

10 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007

Modified form of imatinib becomes more specific

Imatinib (marketed as Gleevec in the US and Glivec in Europe and Australia) is used to treat various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs).

4 Dec 2007

Tasigna gets the green light in the U.S. to treat Chronic Myeloid Leukemia

The Food and Drug Administration (FDA) in the U.S. has given approval for a new drug to treat chronic myeloid leukemia (CML).

30 Oct 2007

Imatinib has ability to cure type of leukemia

In people with chronic myeloid leukemia (CML), the drug Imatinib has been shown to drive cancer into remission, but the disease often returns when treatment is stopped.

3 Oct 2007

Congestive heart failure is rare among leukemia patients who take imatinib

Congestive heart failure rarely occurs among leukemia patients who take imatinib, researchers at The University of Texas M. D. Anderson Cancer Center found after an exhaustive review of the detailed medical histories of 1,276 patients who enrolled in clinical trials for the drug.

10 Sep 2007

Genetics of imatinib resistance in acute lymphoblastic leukemia

In the September 15th issue of Genes & Development, Drs. Richard T. Williams, Willem den Besten, and Charles J. Sherr at Howard Hughes Medical Institute, St. Jude Children's Research Hospital in Memphis TN, lend new insights into how an aggressive form of acute lymphoblastic leukemia (ALL) develops, and how sensitivity to the targeted chemotherapeutic drug, imatinib, can be diminished through interactions between tumor cells and the host microenvironment.

30 Aug 2007

Fingolimod shows promise in 2 lethal leukemias

A new study suggests that an experimental drug being tested for the treatment of multiple sclerosis and to prevent organ rejection might also help people with certain deadly forms of chronic and acute leukemia.

29 Aug 2007

St. Jude discovers factors that accelerate resistance to Gleevec targeted therapy in lymphoblastic leukemia

Results of a study by investigators at St. Jude Children's Research Hospital provide strong evidence for why the drug imatinib (Gleevec), which has revolutionized the treatment of chronic myelogenous leukemia (CML), is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL).

29 Aug 2007

Potential new leukemia drug

In a new study, Danilo Perrotti and colleagues from Ohio State University, Columbus, show that treatment with a drug known as FTY720 prevents disease in a mouse model of many leukemias caused by the cancer protein BCR-ABL (nearly all cases of blast crisis chronic myeloid leukemia [CML-BC] and some cases of acute lymphocytic leukemia [ALL]).

24 Aug 2007

Combination of drugs might decrease the chance of chronic myeloid leukemia returning

Individuals with chronic myeloid leukemia (CML) are treated first with a drug known as imatinib (Gleevec), which targets the protein known to cause the cancer (BCR-ABL).

17 Aug 2007

Detection of gene fusions in prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have discovered how genes turn on the switch that leads to prostate cancer.

3 Aug 2007

Dasatinib shows promise as first treatment for chronic myelogenous leukemia

An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cancer Center.

5 Jun 2007

Unstable leukemia stem cells may predispose patients to drug resistance

The BCR-ABL gene in chronic myeloid leukemia stem cells has a tendency to quickly mutate, and this may help explain why patients are predisposed to resistance to drugs like imatinib that target that gene, according to a study in the May 2 Journal of the National Cancer Institute.

2 May 2007

Discovery of new cell involved with cancer

Scientists have discovered a new type of cell that appears to play a role in the development of cancer – a highly volatile, precancerous stem cell that can either remain benign or become malignant, depending upon environmental cues.

14 Mar 2007

New drug to combat Gastrointestinal graft-vs.-host disease in stem-cell patients shows significant reduction in deaths

Gastrointestinal graft-vs.-host disease is a common and potentially deadly side effect for patients who undergo an allogeneic stem-cell transplant to treat certain blood cancers.

23 Jan 2007